PFM Health Sciences’s Karyopharm Therapeutics KPTI Stock Holding History

PFM Health Sciences’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-54,773	Closed	-$22.4M	–	93
2015 Q2	$22.4M	Sell	54,773 -20,164	-27%	-$8.72M	0.57%	51
2015 Q1	$34.4M	Buy	74,937 +18,248	+32%	+$7.87M	0.95%	41
2014 Q4	$31.8M	Sell	56,689 -18,368	-24%	-$10.4M	0.74%	47
2014 Q3	$39.3M	Buy	75,057 +30,868	+70%	+$17.4M	0.91%	33
2014 Q2	$30.9M	Buy	44,189 +23,550	+114%	+$11M	0.62%	42
2014 Q1	$9.56M	Sell	20,639 -38,662	-65%	-$19.6M	0.17%	62
2013 Q4	$19.8M	Buy	+59,301	New	+$16.4M	0.4%	45

Other funds holding KPTI

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

PFM Health Sciences's KPTI Position: Q3 2015 in Review

PFM Health Sciences sold out of Karyopharm Therapeutics (KPTI) in Q3 2015, closing a stake of 54,773 shares — an estimated $22.4M sold.

PFM Health Sciences first reported a position in KPTI in Q4 2013 and held it in 7 quarters. The position peaked at $39.3M in Q3 2014. 89 funds tracked by Wall St. Rank hold KPTI as of Q3 2015.

PFM Health Sciences reported no remaining Karyopharm Therapeutics position as of Q3 2015 after selling out during the quarter.
PFM Health Sciences sold 54,773 Karyopharm Therapeutics shares in Q3 2015, an estimated $22.4M.
PFM Health Sciences first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 7 quarters.
PFM Health Sciences's Karyopharm Therapeutics position peaked at $39.3M in Q3 2014.
89 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2015.

Based on PFM Health Sciences's 13F filing for Q3 2015, filed 16 Nov 2015.